HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Class Action Wants A Bite Of Post Holdings Subsidiary Making Joint Juice

This article was originally published in The Rose Sheet

Executive Summary

Premier Nutrition is targeted in a class action complaint alleging false health benefit claims for its Joint Juice joint health supplement, including that the product would support and nourish cartilage and lubricate joints.

You may also be interested in...



Pharmavite Agrees To $1.9M Settlement In TripleFlex Class Action

Pharmavite will pay $1.9m and discontinue joint improvement claims for four Nature Made TripleFlex glucosamine products under terms of a class-action settlement in a six-year dispute over the truthfulness of joint renewal and rejuvenation claims.

Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane

Steven Cahillane, who left his post as president of Coca-Cola Co.’s Americas division in 2013, is moving to NBTY to replace Jeffrey Nagel after the supplement manufacturer and retailer reported flat sales for its most recent earnings period and after net income dropped nearly 12% during the firm’s previous fiscal year.

Cereal Firm Post Expands Into Supplements With Premier Nutrition Pick-Up

Seeking to diversify its portfolio for more dramatic sales growth, Post Holdings acquires Premier Nutrition, maker of Joint Juice and Premier Protein supplements. The $180 million transaction follows closely Post’s purchase of probiotic bar and natural cereal maker Attune Foods.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel